Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project

References

• Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. Gastroenterology. 2003;125(5):1544–1546. doi:10.1016/j.gastro.2003.05.009
   PubMedGoogle Scholar
• El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10. doi:10.3899/jrheum.091461
   PubMedGoogle Scholar
• Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care. 2002;8(21 Suppl):S664–S681; quiz S682–S685.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680–686. doi:10.1038/s41577-021-00603-1
   PubMed Web of Science ®Google Scholar
• Trifirò G, Gini R, Barone-Adesi F, et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 2019;42(3):347–363. doi:10.1007/s40264-018-0732-5
   PubMed Web of Science ®Google Scholar
• Marcianò I, Ingrasciotta Y, Giorgianni F, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from Five Italian Centres in the years 2009–2014. BioDrugs. 2016;30(4):295–306. doi:10.1007/s40259-016-0175-4
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Giorgianni F, Bolcato J, et al. How much are biosimilars used in clinical practice? A Retrospective Italian Population-based study of erythropoiesis-stimulating agents in the years 2009–2013. BioDrugs. 2015;29(4):275–284. doi:10.1007/s40259-015-0132-7
   PubMed Web of Science ®Google Scholar
• Trifirò G, Isgrò V, Ingrasciotta Y, et al. Large-Scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the VALORE project. BioDrugs. 2021;35(6):749–764. doi:10.1007/s40259-021-00498-3
   PubMed Web of Science ®Google Scholar
• Canova C, Simonato L, Barbiellini Amidei C, et al. A systematic review of case-identification algorithms for 18 conditions based on Italian Healthcare Administrative Databases: a study protocol. Epidemiol Prev. 2019;43(4 Suppl 2):8–16. doi:10.19191/EP19.4.S2.P008.089
   PubMed Web of Science ®Google Scholar
• Research C for DE and. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data sets. U.S. Food and Drug Administration; 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic. Accessed May 27, 2022.
   Google Scholar
• Bartolini C, Roberto G, Girardi A, et al. Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications. Front Oncol. 2023;13:1059109. doi: 10.3389/fonc.2023.1059109
   PubMed Web of Science ®Google Scholar
• Spini A, Rosellini P, Bellan C, et al. Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry. PLoS One. 2022;17(6):e0269232. doi:10.1371/journal.pone.0269232
   PubMed Web of Science ®Google Scholar
• Conway G, Velonias G, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. The impact of co-existing immune mediated disease on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(6):814–823. doi:10.1111/apt.13940
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Jin Y, Foti SS, et al. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study. Clin Rheumatol. 2023;42(4):1047–1059. doi:10.1007/s10067-022-06478-4
   PubMed Web of Science ®Google Scholar
• Macca L, Li Pomi F, Ingrasciotta Y, Morrone P, Trifirò G, Guarneri C. Hidradenitis suppurativa and psoriasis: the odd couple. Front Med. 2023;10:1208817. doi:10.3389/fmed.2023.1208817
   Web of Science ®Google Scholar
• Asgari MM, Wu JJ, Gelfand JM, et al. Validity of Diagnostic Codes and Prevalence of Psoriasis and Psoriatic Arthritis in a Managed Care Population, 1996–2009. Pharmacoepidemiol Drug Saf. 2013;22(8):842–849. doi:10.1002/pds.3447
   PubMed Web of Science ®Google Scholar
• Dobson-Belaire W, Goodfield J, Borrelli R, Liu FF, Khan ZM. Identifying psoriasis and psoriatic arthritis patients in retrospective databases when diagnosis codes are not available: a validation study comparing medication/prescriber visit-based algorithms with diagnosis codes. Value Health. 2018;21(1):110–116. doi:10.1016/j.jval.2017.06.012
   PubMed Web of Science ®Google Scholar
• Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13(1):R32. doi:10.1186/ar3260
   PubMed Web of Science ®Google Scholar
• Convertino I, Cazzato M, Giometto S, et al. Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases. Sci Rep. 2021;11(1):20314. doi:10.1038/s41598-021-98321-0
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Spini A, L’Abbate L, et al. (2024). Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project. Pharmacological Research. 2024;200:107074. doi:10.1016/j.phrs.2024.107074
   PubMed Web of Science ®Google Scholar
• Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x
   PubMed Web of Science ®Google Scholar
• Roberto G, Spini A, Bartolini C, et al. Real word evidence on rituximab utilization: combining administrative and hospital-pharmacy data. PLoS One. 2020;15(3):e0229973. doi:10.1371/journal.pone.0229973
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Isgrò V, Foti SS, et al. Testing of coding algorithms for inflammatory bowel disease identification, as indication for use of biological drugs, using a claims database from Southern Italy. Clin Epidemiol. 2023;15:309–321. doi:10.2147/CLEP.S383738
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Ciampichini R, Cazzaniga S, Sampietro G, Zucchi A, Naldi L. Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy. Arch Dermatol Res. 2021;313(4):255–261. doi:10.1007/s00403-020-02101-1
   PubMed Web of Science ®Google Scholar
• Perrone V, Giacomini E, Sangiorgi D, et al. Treatment pattern analysis and health-care resource consumption on patients with psoriatic arthritis or ankylosing spondylitis treated with biological drugs in a Northern Italian Region. Ther Clin Risk Manag. 2020;16:509–521. doi:10.2147/TCRM.S248390
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Perrone V, Sangiorgi D, et al. Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting. Patient Prefer Adherence. 2019;13:187–194. doi:10.2147/PPA.S178603
   PubMed Web of Science ®Google Scholar
• Perrone V, Losi S, Rogai V, et al. Treatment patterns and pharmacoutilization in patients affected by rheumatoid arthritis in Italian Settings. Int J Environ Res Public Health. 2021;18(11):5679. doi:10.3390/ijerph18115679
   PubMed Web of Science ®Google Scholar
• Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA dermatol. 2014;150(9):937–944. doi:10.1001/jamadermatol.2014.691
   PubMed Web of Science ®Google Scholar
• French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008;28(6):889–893. doi:10.1097/IAE.0b013e31816576ef
   PubMed Web of Science ®Google Scholar
• Klein NP, Ray P, Carpenter D, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010;28(4):1062–1068. doi:10.1016/j.vaccine.2009.10.115
   PubMed Web of Science ®Google Scholar
• Khalsa A, Liu G, Kirby JS. Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(4):609–614. doi:10.1016/j.jaad.2015.06.053
   PubMed Web of Science ®Google Scholar
• Dubreuil M, Peloquin C, Zhang Y, Choi HK, Inman RD, Neogi T. Validity of ankylosing spondylitis diagnoses in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2016;25(4):399–404. doi:10.1002/pds.3952
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang H, Dai SM. Differentiating psoriatic arthritis sine psoriasis from seronegative rheumatoid arthritis-Experiences from five patients. Int J Rheum Dis. 2022;25(9):1088–1092. doi:10.1111/1756-185X.14385
   PubMed Web of Science ®Google Scholar
• Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology. 2019;58(2):e3–e42. doi:10.1093/rheumatology/key208
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. doi:10.3389/fphar.2019.00279
   PubMed Web of Science ®Google Scholar